"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Panhematin Consumer (continued)
Do not start or stop any medicine without doctor or pharmacist approval.
This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If overdose is suspected, contact a poison control center or emergency room immediately. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: signs of kidney problems (such as change in the amount of urine).
NOTES: Laboratory and/or medical tests (e.g., blood tests, urine tests) should be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.
This drug will not fix nerve damage that can occur with untreated acute porphyria attacks. If given early enough, though, it can decrease the amount of permanent nerve damage.
MISSED DOSE: If you miss a dose, contact your doctor or pharmacist immediately to establish a new dosing schedule.
STORAGE: Not applicable. This medication is given in a hospital or clinic and will not be stored at home.
Information last revised December 2013. Copyright(c) 2013 First Databank, Inc.
Additional Panhematin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.